Source: International Congress 2017 – Update on community acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Ceccato (Ituzaingo, Buenos Aires, Argentina). Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP?. 473

Member's Comments

No comment yet.

Related content which might interest you: Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin Source: Eur Respir J 2003; 22: Suppl. 45, 543s Year: 2003 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Treatment guidelines for CAP and the role of macrolides Source: Annual Congress 2004 - Developments in the management of lower respiratory tract infections Year: 2004 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP) Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010